AN2 Therapeutics, Inc. (ANTX)

The company reported its third-quarter 2025 financial results, announced a research collaboration with GSK for tuberculosis, and received a third year of funding from the Gates Foundation on November 12, 2025. On March 3, 2026, AN2 Therapeutics announced its plans to advance oral epetraborole into a Phase 2 study for polycythemia vera (PV). The company announced a $40 million private placement financing on March 9, 2026. On March 17, 2026, AN2 Therapeutics reported its fourth-quarter and full-year 2025 financial results, highlighting progress in its business and scientific endeavors. The company announced the initiation of a Phase 2 investigator-initiated clinical trial of epetraborole for Mycobacterium abscessus Complex Lung Disease on March 31, 2026. AN2 Therapeutics established a new $80 million at-the-market (ATM) stock sale facility with Jefferies, simultaneously terminating a previous ATM program on April 9, 2026. The company announced its participation in the 2026 Stifel Virtual Targeted Oncology Forum on May 7, 2026. Over the past year, AN2 Therapeutics' stock price has experienced significant growth.

As a clinical-stage biopharmaceutical company with products still under development, there is no information available regarding demand seasonality for AN2 Therapeutics, Inc.'s products and services.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics from its boron chemistry platform. The company operates in the Healthcare sector, specifically in Biotechnology and Pharmaceuticals & Biotech industries, addressing rare, chronic, and serious infectious diseases with high unmet medical needs, as well as oncology. Its major product candidates include Epetraborole (AN2-502998) for NTM lung disease, acute melioidosis, and polycythemia vera (PV), AN2-502998 for chronic Chagas disease, and early-stage oncology programs targeting solid tumor indications, including ENPP1 and PI3Kα.

AN2 Therapeutics, Inc. is headquartered in Menlo Park, California, United States. It has a license agreement with Brii Biosciences Limited for epetraborole in China, Hong Kong, Taiwan, and Macau, and a research collaboration with GSK plc to develop new therapies for tuberculosis (TB).

AN2 Therapeutics' reputation is shaped by its scientific advancements and strategic collaborations. The company's focus on developing treatments for diseases with high unmet medical needs contributes positively to its standing. Recent announcements regarding clinical trials and the progression of its programs demonstrate active development. Collaborations with entities like GSK and funding from the Gates Foundation underscore its scientific credibility. There is no information indicating any events that have negatively affected AN2 Therapeutics, Inc.'s brand reputation in the past year.

AN2 Therapeutics, Inc. has 43 institutional owners and shareholders, holding a total of 8,121,034 shares. Major institutional owners include Almitas Capital LLC, Vanguard Group Inc, Pfizer Inc, Stonepine Capital Management, LLC, Bank Of Nova Scotia, Landscape Capital Management, L.l.c., Bank Of Montreal /can/, Bank Of America Corp /de/, Renaissance Technologies Llc, and BlackRock, Inc. Hedge funds hold 28.8% of the company, institutions 22.7%, the general public 24.5%, VC/PE Firms 15.4%, and individual insiders 6.03%.